Anavex Life Sciences (AVXL) Non-Current Assets (2011 - 2019)
Anavex Life Sciences recorded quarterly Non-Current Assets of $151133.0 in Q2 2019, down 1.56% quarter-over-quarter from $153529.0 in Q3 2018, and up 188.44% year-over-year from $52396.0 in Q2 2018.
Anavex Life Sciences' Non-Current Assets history runs 9 years deep, the most recent figure standing at $151133.0 for Q2 2019.
- In Q2 2019, Non-Current Assets rose 188.44% year-over-year to $151133.0; the TTM figure through Jun 2020 stood at $151133.0 (down 50.39% YoY), while the FY2018 annual figure was $153529.0, up 193.02% from the prior year.
- Non-Current Assets came in at $151133.0 for Q2 2019 at Anavex Life Sciences, down from $153529.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $153529.0 in Q3 2018 to a low of $1501.0 in Q2 2015.
- A 5-year average of $65323.1 and a median of $52396.0 in 2016 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets sank 99.87% in 2015 and soared 193.02% in 2018, its largest moves.
- Anavex Life Sciences' Non-Current Assets stood at $1501.0 in 2015, then jumped by 3390.74% to $52396.0 in 2016, then changed by 0.0% to $52396.0 in 2017, then jumped by 193.02% to $153529.0 in 2018, then dropped by 1.56% to $151133.0 in 2019.
- According to Business Quant data, Non-Current Assets over the past three periods registered $151133.0, $153529.0, and $52396.0 for Q2 2019, Q3 2018, and Q2 2018 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 151,133.00 |
| Sep 30, 2018 | 153,529.00 |
| Jun 30, 2018 | 52,396.00 |
| Mar 31, 2018 | 83,339.00 |
| Dec 31, 2017 | 52,396.00 |
| Sep 30, 2017 | 52,396.00 |
| Jun 30, 2017 | 52,396.00 |
| Sep 30, 2016 | 52,396.00 |
| Jun 30, 2015 | 1,501.00 |
| Mar 31, 2015 | 1,749.00 |
| Dec 31, 2014 | 1,998.00 |
| Sep 30, 2014 | 2,247.00 |
| Jun 30, 2014 | 1.12 Mn |
| Mar 31, 2014 | 1.07 Mn |
| Dec 31, 2013 | 2,135.00 |
| Dec 31, 2012 | 111.00 |
| Sep 30, 2012 | 576.00 |
| Jun 30, 2012 | 1,040.00 |
| Mar 31, 2012 | 1,505.00 |
| Sep 30, 2011 | 2,434.00 |